{"id":76373,"date":"2013-04-16T03:52:02","date_gmt":"2013-04-16T07:52:02","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/penn-medicine-researcher-awarded-prestigious-grand-prix-scientifique-by-the-institut-de-france.php"},"modified":"2013-04-16T03:52:02","modified_gmt":"2013-04-16T07:52:02","slug":"penn-medicine-researcher-awarded-prestigious-grand-prix-scientifique-by-the-institut-de-france","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/penn-medicine-researcher-awarded-prestigious-grand-prix-scientifique-by-the-institut-de-france.php","title":{"rendered":"Penn Medicine researcher awarded prestigious Grand Prix Scientifique by the Institut de France"},"content":{"rendered":"<p><p>Public  release date: 15-Apr-2013  [ |   E-mail   |  Share    ]  <\/p>\n<p>    Contact: Karen Kreeger    <a href=\"mailto:karen.kreeger@uphs.upenn.edu\">karen.kreeger@uphs.upenn.edu<\/a>    215-349-5658    University of Pennsylvania    School of Medicine<\/p>\n<p>    PHILADELPHIA  Garret FitzGerald MD, FRS, chairman of the    Pharmacology Department and director of the Institute for    Translational Medicine and Therapeutics, Perelman School of    Medicine, University of Pennsylvania, has been awarded the 2013    Grand Prix Scientifique by the Institut de France.  <\/p>\n<p>    FitzGerald shares the prize with Carlo Patrono MD, chairman of    Pharmacology at the Catholic University, Rome. The award is    based on the recommendation of the International Scientific    Council of the Board of Directors of the Lefoulon-Delalande    Foundation, Paris. The prize will be awarded under the    presidency of the Chancellor of the Institut de France and the    President of the French Academy of Sciences on June 5th, 2013.    The Grand Prix Lefoulon-Delalande, valued at 500,000 euros    ($650,000) is one of the largest prizes for scientific    accomplishment and is considered the world's most prestigious    prize for cardiovascular research.  <\/p>\n<p>    FitzGerald and Patrono share the prize for their development of    low-dose aspirin for the prevention of cardiovascular disease.    Their work used novel approaches to assess the formation of    short-lived fats in the body called prostaglandins that play a    key role in the development of blood clotting. They discovered    how lower doses of aspirin than had been previously used to    treat pain and inflammation act on blood cells called platelets    to shut down their role in blocking arteries to cause heart    attacks and strokes. Low-dose aspirin is now used for this    purpose throughout the world and has saved the lives of tens of    millions of people.  <\/p>\n<p>    \"I am delighted to receive this honor,\" said FitzGerald.    \"However, it reflects the creativity, focus and hard work of so    many people with whom I have been privileged to work. It is a    particular pleasure to share this prize with Carlo, with whom I    have collaborated and competed, but most importantly, shared a    special friendship for more than 30 years.\"  <\/p>\n<p>    Aside from his work on aspirin, FitzGerald was the first to    predict and then mechanistically explain the cardiovascular    hazards from such nonsteroidal antinflammatory drugs as Vioxx    and Celebrex. His laboratory has discovered novel indices of    oxidant stress and was the first to describe the molecular    clock in the cardiovascular system. Among his awards in the    past year have been the Scheele Award from the Swedish Academy    of the Pharmaceutical Science and the Lucian Award from McGill    University.  <\/p>\n<p>    ###  <\/p>\n<p>    Penn Medicine is one of the world's leading academic medical    centers, dedicated to the related missions of medical    education, biomedical research, and excellence in patient care.    Penn Medicine consists of the Raymond and Ruth Perelman School    of Medicine at the University of Pennsylvania (founded in 1765    as the nation's first medical school) and the University of    Pennsylvania Health System, which together form a $4.3 billion    enterprise.  <\/p>\n<p>    The Perelman School of Medicine has been ranked among the top    five medical schools in the United States for the past 16    years, according to U.S. News & World Report's survey of    research-oriented medical schools. The School is consistently    among the nation's top recipients of funding from the National    Institutes of Health, with $398 million awarded in the 2012    fiscal year.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Read the rest here: <\/p>\n<p><a target=\"_blank\" href=\"http:\/\/www.eurekalert.org\/pub_releases\/2013-04\/uops-pmr041513.php\" title=\"Penn Medicine researcher awarded prestigious Grand Prix Scientifique by the Institut de France\">Penn Medicine researcher awarded prestigious Grand Prix Scientifique by the Institut de France<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Public release date: 15-Apr-2013 [ | E-mail | Share ] Contact: Karen Kreeger <a href=\"mailto:karen.kreeger@uphs.upenn.edu\">karen.kreeger@uphs.upenn.edu<\/a> 215-349-5658 University of Pennsylvania School of Medicine PHILADELPHIA Garret FitzGerald MD, FRS, chairman of the Pharmacology Department and director of the Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, has been awarded the 2013 Grand Prix Scientifique by the Institut de France. FitzGerald shares the prize with Carlo Patrono MD, chairman of Pharmacology at the Catholic University, Rome.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medicine\/penn-medicine-researcher-awarded-prestigious-grand-prix-scientifique-by-the-institut-de-france.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[35],"tags":[],"class_list":["post-76373","post","type-post","status-publish","format-standard","hentry","category-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/76373"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=76373"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/76373\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=76373"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=76373"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=76373"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}